Hosted on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.
Rutland Herald

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
The Desert Sun

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4

n = number of patients included in each study group for HbA1c and body weight efficacy assessments Abbreviations: EOS: End of Study (week 16); Wk: week; BID: twice daily; CBD: cannabidiol; QD: once ...

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Assessments of the magnitude of decreases in glycated haemoglobin (" HbA1c "), as a primary blood test for blood sugar levels, and body weight were the major secondary efficacy endpoints of the Study.